1417694-03-1

Basic information

• Product Name: {4-[((S)-2-amino-3-phenyl-propionylamino)-methyl]-benzyl}-carbamic acid tert-butyl ester
• Synonyms: {4-[((S)-2-amino-3-phenyl-propionylamino)-methyl]-benzyl}-carbamic acid tert-butyl ester
• CAS NO: 1417694-03-1
• Molecular Weight: 383.491
• Mol File: 1417694-03-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: {4-[((S)-2-amino-3-phenyl-propionylamino)-methyl]-benzyl}-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: {4-[((S)-2-amino-3-phenyl-propionylamino)-methyl]-benzyl}-carbamic acid tert-butyl ester(1417694-03-1)
• EPA Substance Registry System: {4-[((S)-2-amino-3-phenyl-propionylamino)-methyl]-benzyl}-carbamic acid tert-butyl ester(1417694-03-1)

Safety Data

• Hazardous Substances Data: 1417694-03-1(Hazardous Substances Data)

Upstream product

• 1161-13-3 N-Cbz-L-Phe 
• 108468-00-4 tert-butyl 4-(aminomethyl)benzylcarbamate 
• 3397-32-8 N-(benzyloxycarbonyl)-phenylalanine-N-hydroxysuccinimide ester 
• 1417694-02-0 (S)-(1-((4-(((tert-butoxycarbonyl)amino)methyl)benzyl)amino)-1-oxo-3-phenylpropyl-2-yl)carbamic acid benzyl ester 

Downstream Products

• 1417694-06-4 [(R)-1-{(S)-1-[4-(tert-butoxycarbonylaminomethyl)benzylcarbamoyl]-2-phenyl-ethylcarbamoyl}-2-(4-ethoxyphenyl)ethyl]carbamic acid benzyl ester 
• 1417694-07-5 [4-({(S)-2-[(R)-2-benzoylamino-3-(4-ethoxy-phenyl)-propionylamino]-3-phenyl-propionylamino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 1417694-08-6 N-[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride 
• 1417694-05-3 [(R)-1-{(S)-1-[4-(tert-butoxycarbonylamino-methyl)-benzylcarbamoyl]-2-phenyl-ethylcarbamoyl}-2-(4-ethoxy-phenyl)-ethyl]-carbamic acid benzyl ester 

Relevant articles and documents

Tetracyclic compound as plasma kallikrein inhibitor and application thereof

The invention provides a tetracyclic plasma kallikrein inhibitor compound which is novel in structure, good in activity and high in selectivity, and can be widely applied to prevention or treatment of diseases related to plasma kallikrein activity.

Tricyclic compound as plasma kallikrein inhibitor and application thereof

The invention provides a tricyclic plasma kallikrein inhibitor compound which is novel in structure, good in activity and high in selectivity. The tricyclic plasma kallikrein inhibitor compound can be widely applied to prevention or treatment of diseases related to plasma kallikrein activity.

BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.